Abstract
Simple SummaryIn patients with prostate cancer, lymph node involvement is a risk factor of relapse. Current guidelines recommend extended lymph node dissection to better stage the disease. However, such a surgical procedure is associated with a higher morbidity than limited lymph node dissection. A better selection of patients is thus essential. Radiomics features are quantitative features automatically extracted from medical imaging. Combining clinical and radiomics features, a machine learning-based model seemed to provide added predictive performance compared to state of the art models regarding the risk prediction of lymph-node involvement in prostate cancer patients.Significant advances in lymph node involvement (LNI) risk modeling in prostate cancer (PCa) have been achieved with the addition of visual interpretation of magnetic resonance imaging (MRI) data, but it is likely that quantitative analysis could further improve prediction models. In this study, we aimed to develop and internally validate a novel LNI risk prediction model based on radiomic features extracted from preoperative multimodal MRI. All patients who underwent a preoperative MRI and radical prostatectomy with extensive lymph node dissection were retrospectively included in a single institution. Patients were randomly divided into the training (60%) and testing (40%) sets. Radiomic features were extracted from the index tumor volumes, delineated on the apparent diffusion coefficient corrected map and the T2 sequences. A ComBat harmonization method was applied to account for inter-site heterogeneity. A prediction model was trained using a neural network approach (Multilayer Perceptron Network, SPSS v24.0©) combining clinical, radiomic and all features. It was then evaluated on the testing set and compared to the current available models using the Receiver Operative Characteristics and the C-Index. Two hundred and eighty patients were included, with a median age of 65.2 y (45.3–79.6), a mean PSA level of 9.5 ng/mL (1.04–63.0) and 79.6% of ISUP ≥ 2 tumors. LNI occurred in 51 patients (18.2%), with a median number of extracted nodes of 15 (10–19). In the testing set, with their respective cutoffs applied, the Partin, Roach, Yale, MSKCC, Briganti 2012 and 2017 models resulted in a C-Index of 0.71, 0.66, 0.55, 0.67, 0.65 and 0.73, respectively, while our proposed combined model resulted in a C-Index of 0.89 in the testing set. Radiomic features extracted from the preoperative MRI scans and combined with clinical features through a neural network seem to provide added predictive performance compared to state of the art models regarding LNI risk prediction in PCa.
Highlights
With 335,230 new estimated cases/year and 69,945 estimated deaths in 2020 in Europe alone [1], prostate cancer (PCa) is the most common cancer among men in western countries
We aimed to develop and internally validate a neural networks (NN) radiomic-based lymph node involvement (LNI) prediction model
From 2010 to 2018, 552 patients underwent radical prostatectomy with extensive lymph node dissection (eLND), among which 280 patients were included with 272 excluded patients due to unavailable or incomplete magnetic resonance imaging (MRI) (n = 266) and unanalyzable MRI (n = six)
Summary
With 335,230 new estimated cases/year and 69,945 estimated deaths in 2020 in Europe alone [1], prostate cancer (PCa) is the most common cancer among men in western countries. The decision to perform LND in clinically LNI-free patients (cN0) is guided by the probability of nodal metastases, with several models developed for the prediction of LNI risk: the National Comprehensive Cancer Network (NCCN) chooses 2% as a cut-off according to a nomogram developed by the Memorial Sloan Kettering Cancer Centre, whereas the European Association of Urology (EAU) guidelines [8] recommends it for patients with a probability of LNI over 5% based on 2012-Briganti nomogram. Several clinical models were presented for LNI risk prediction [9,10,11,12,13,14]. Gandaglia et al developed a new promising algorithm using qualitative data from MRIs in patients with targeted biopsies [16]. Even if targeted combined with systematic biopsies provide a better assessment of the Gleason score [17], software-based fusion targeted biopsies require special logistics and a certain cost [18], which explains its under-utilization compared to cognitive fusion, leaving place for better LNI risk assessment tools
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.